Taken together, these studies implicate TGFβ-blockade and the remodeling of CAF dynamics as advantageous strategies to augment the cancer immunity cycle, supporting future studies aimed at elucidating innovative opportunities to strategically reprogram CAFs in the tumor microenvironment. Here, TGFB1 is linked to cancer.